Literature DB >> 2843611

Stage I nonseminomatous germ cell testicular tumor: prediction of metastatic potential by primary histopathology.

C Y Fung1, L A Kalish, G L Brodsky, J P Richie, M B Garnick.   

Abstract

A study of 60 patients with clinical stage I nonseminomatous germ cell testicular tumor (NSGCT) was conducted to identify prognostic factors that may predict the likelihood of metastasis. Clinical features and histopathologic features of the primary testicular tumor were examined and analyzed for correlations with the presence of retroperitoneal nodal metastasis documented by surgery (N+) and with development of relapse (R+). Pathologic tumor stage greater than or equal to 2, with tumor extension into the tunica albuginea, rete testis, epididymis, or spermatic cord, was correlated with an increased rate of N+ compared with pathologic tumor stage I (P = .001). Vascular invasion was correlated with a higher rate of N+ (P = .05) and had a similar association with R+ (P = .08). Tumors containing less than 50% teratoma were found to have a higher rate of N+ than tumors with greater than or equal to 50% teratoma (P = .02). Based on the identified prognostic factors, a model for predicting the probability of retroperitoneal nodal metastasis in clinical stage I patients is proposed. The risk factors for nodal metastasis are: pathologic tumor stage greater than or equal to 2, vascular invasion, and less than 50% teratoma. Patients with none of the risk factors are considered at low risk and may be offered orchiectomy alone with surveillance for initial treatment. Patients with all three risk factors are at high risk and should be treated with a retroperitoneal lymph node dissection (RPLND) or possibly chemotherapy. Patients with one or two risk factors are at intermediate risk; it is recommended that they undergo RPLND. This risk model facilitates a rational approach to the management of clinical stage I NSGCT.

Entities:  

Mesh:

Year:  1988        PMID: 2843611     DOI: 10.1200/JCO.1988.6.9.1467

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  9 in total

Review 1.  Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.

Authors:  C Bokemeyer; M A Kuczyk; J Serth; J T Hartmann; H J Schmoll; U Jonas; L Kanz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors.

Authors:  J Baniel; B J Roth; R S Foster; J P Donohue
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

Review 3.  Controversies in the management of stage 1 non-seminomatous germ cell tumors.

Authors:  Sarah Coleman; Andrew Stephenson
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 4.  Biomarkers of disease recurrence in stage I testicular germ cell tumours.

Authors:  Peter Lesko; Michal Chovanec; Michal Mego
Journal:  Nat Rev Urol       Date:  2022-08-26       Impact factor: 16.430

5.  Significance of presence of teratomatous elements in the primary tumour of testicular cancer.

Authors:  K Suzuki; H Nakazato; K Matsumoto; K Kurokawa; T Suzuki; K Suzuki; H Yamanaka
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

6.  Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis.

Authors:  Soner Guney; Nese Guney; Nurettin Cem Sonmez; Erbil Ergenekon
Journal:  Med Oncol       Date:  2008-09-26       Impact factor: 3.064

7.  Sentinel node biopsy in clinical stage I testicular cancer enables early detection of occult metastatic disease.

Authors:  Joost M Blok; J Martijn Kerst; Erik Vegt; Oscar R Brouwer; Richard P Meijer; J L H Ruud Bosch; Axel Bex; Henk G van der Poel; Simon Horenblas
Journal:  BJU Int       Date:  2019-03-28       Impact factor: 5.588

8.  Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.

Authors:  João Lobo; Ad J M Gillis; Annette van den Berg; Leendert H J Looijenga
Journal:  BMC Cancer       Date:  2020-08-05       Impact factor: 4.430

Review 9.  Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis.

Authors:  Joost M Blok; Ilse Pluim; Gedske Daugaard; Thomas Wagner; Katarzyna Jóźwiak; Erica A Wilthagen; Leendert H J Looijenga; Richard P Meijer; J L H Ruud Bosch; Simon Horenblas
Journal:  BJU Int       Date:  2020-01-08       Impact factor: 5.588

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.